
Swedish healthcare company Readily Diagnostics has received a grant of around €811,000 (9 million SEK) from the Gates Foundation. The company develops point-of-care diagnostic tests that can provide results quickly.
The funding will help Readily Diagnostics develop an affordable test for three common sexually transmitted infections (STIs): chlamydia, gonorrhea and trichomoniasis.
The company will use the grant for early research and testing to check whether the new diagnostic test can work effectively. This work will also cover preparing patient samples and detecting antimicrobial resistance.
Readily Diagnostics will also create a complete plan for developing the test into a finished product. The goal is to make STI testing more affordable and accessible.
“Readily is committed to delivering accessible molecular diagnostics. A diagnosis should not depend on where you happen to live,” says Liza Löf, CEO of Readily Diagnostics. “This grant from the Gates Foundation lets us show that an accurate STI test can also be simple and affordable enough to use anywhere. That is the whole point of the technology we have built.”
Founded in 2022 as a spinout from Uppsala University, Readily Diagnostics develops fast and accurate tests for infectious diseases. The company is now focusing on three common STIs: chlamydia, gonorrhea and trichomoniasis.
These infections affect hundreds of millions of people around the world every year. However, getting an accurate diagnosis can be difficult, especially in low- and middle-income countries.
In many of these countries, doctors often treat patients based only on their symptoms because testing can be too expensive, too slow or simply not available. This can lead to missed infections, unnecessary antibiotic use and continued spread of the diseases.
Readily Diagnostics is developing a point-of-care testing platform that can provide molecular test results close to the patient. This means the test can be used without sending samples to a central laboratory.
The platform uses the same padlock-probe technology that Readily developed for respiratory infection testing. The company is now adapting this technology to detect sexually transmitted infections.